enGene Holdings Inc. (ENGN) Stock

NASDAQ: ENGNDevelops non-viral gene therapy solutions for gastrointestinal and liver diseases, utilizing its proprietary gene delivery platform.

enGene stock price chart

ENGN interactive chart →

ENGN stock quote & key statistics

enGene earnings per share

Income →

Earnings per share

enGene revenue & net income

Income →

RevenueNet income

enGene annual financials

Income statement →

enGene Holdings Inc. revenue, net income and EPS by fiscal year
Fiscal year	Revenue	Net income	EPS
FY2025	$0	-$117.3M	-$2.29
FY2024	$0	-$55.1M	-$1.50
FY2023	$0	-$99.9M	-$4.65
FY2022	$0	-$24.5M	-$0.02
FY2021	$0	-$23.4M	$0.00

Fiscal year ending October 31. Source: company filings via EODHD.

About enGene Holdings Inc.

enGene Holdings Inc., operating through its subsidiary enGene, Inc., is a clinical-stage biotechnology firm specializing in the development of genetic medicines delivered to mucosal tissues and various organs.

Leading its portfolio is EG-70 (detalimogene voraplasmid), a non-viral immunotherapy designed specifically for patients with non-muscle invasive bladder cancer and carcinoma-in-situ (Cis) who have not responded to Bacillus Calmette-Guerin treatment.

Established in 2023 and headquartered in Saint-Laurent, Canada, enGene Holdings Inc. is committed to pioneering advancements in genetic medicine delivery. The company's innovative approach holds promise for addressing critical medical needs and advancing treatment options in oncology and beyond.

enGene stock FAQ

What is the enGene stock ticker symbol?

enGene Holdings Inc. trades on the NASDAQ under the ticker symbol ENGN.

What sector and industry is enGene in?

enGene Holdings Inc. is classified in the Healthcare sector, Biotechnology industry.

How many employees does enGene have?

enGene Holdings Inc. has about 81 full-time employees.

What were enGene's revenue and earnings last fiscal year?

enGene reported revenue of $0 and net income of -$117.3M in fiscal 2025, with earnings per share of -$2.29.

When did enGene go public?

enGene stock began trading on November 1, 2023.

Biotechnology stocks

All Healthcare stocks →